Hypertension is the most prevalent treatable c ardiovasc ular disease affec ting approximately one in four adults or 1 4 0 million USA residents. It affec ts men and women in all soc ioec onomic groups equally. If untreated, hypertension is a major c ause of stroke, c oronary heart disease and renal failure as well as other c onditions. Easily diagnosed, and in most instanc es readily c ontrolled, hypertension is often unsuspec ted or inadequately treated.
The c auses of high blood pressure are a bit of a mystery. Ac c ording to the National Heart, Lung and Blood Institute, as many as 2 5 % of adult Americ ans suffer from high blood pressure. Results of the Croatian national survey performed in 1 9 9 7 in a sample of 5 8 4 0 persons of both sexes, aged 1 8 -6 5 , showed about 2 8 % adults to be hypertensive ( BP> 1 4 0 /9 0 mm Hg) , with a signific antly greater prevalenc e rec orded in men ( 3 2 %) than in women ( 2 4 %) .
T he causes of high blood pressure
In most people, no spec ific c ause of high blood pressure c an be identified. It appears to be a distinc t entity, due in part to a genetic predisposition ( essential hyper tension) . As much as 9 5 % of the people with high blood pr essur e have essential hyper tension. The pr obability of developing hyper tension incr eases with age. Mor e than half of all per sons aged 6 5 ar e hyper tensive. Tr eating high blood pr essur e significantly decr eases the r isk of str oke, myocardial infar ction and car diovascular death. Another type of high blood pr essur e called secondar y hyper tension is mor e common in younger individuals, usually due to some other pr oblem ( for example, per sons taking bir th contr ol pills, r enovascular patients, etc.) .
About 5 % of patients requiring hypertension treatment c an trac e their high blood pressure to a physic al c ause suc h as kidney disease, however for 9 5 % of patients who undergo hypertension treatment the c auses of high blood pressure are unknown.
High r isk gr oups. Afric an Americ ans have a greater risk of developing hypertension than Cauc asian Americ ans. Men are more likely to develop high blood pressure than women, and to develop hypertension at an earlier age. After the menopause, women bec ome more susc eptible to high blood pressure. Hypertension is a major c ontributor to c oronary heart disease and stroke, the two leading c auses of death among adults worldwide. It is a silent epidemic affec ting both sexes and rising with age. Hypertension, whic h affec ts approximately one in four adults in the USA, has an important role as an aetiologic al fac tor in the most prevalent treatable c onditions suc h as c ardiovasc ular disease. Untreated hypertension is a major c ause of stroke, c oronary heart disease ( myoc ardial infarc tion) , c ongestive heart failure and renal failure, as well as other c onditions.
Major risk factors

Smoking
Hypertension as a potentially serious c ondition produc es various symptoms like sweating, palpitation, headac he, and dizziness. Numerous sc ientific studies have estimated that between 5 5 and 7 0 million of the 1 4 0 million adults suffering from hypertension are unaware of it, and of those who know, fewer than half may be appropriately treated. Only 2 7 % of all hypertensive patients in the USA are being treated appropriately. It is well known that the treatment of high blood pressure signific antly dec reases the risk of developing potentially fatal c onditions.
In general, high blood pressure, or hypertension is defined as a systolic pressure of 1 4 0 mm Hg or greater and/or diastolic pressure of 9 0 mm Hg or greater, c onsidered to be above the normal range. Definition of hypertension ac c ording to the guidelines of World Health Organization -International Soc iety of Hypertension ( 1 9 9 9 ) is presented in Table 2 and c lassific ation of blood pressure for adults ac c ording to Joint National Committee in Table 3 .
Diagnosis
Hypertension is often referred to as a silent killer bec ause the symptoms are often unnotic eable until c omplic ations oc c ur. High blood pressure has a long asymptomatic period despite existing c ardiovasc ular damage or kidney failure. The diagnosis of hypertension depends on c areful blood pressure measurements and evaluation of the major risk fac tors. Two readings have to be taken together and averaged. Laboratory testing inc ludes blood tests ( haemoglobin and pac ked red c ell volume, elec trolytes, fasting blood gluc ose, serum lipids, serum c reatinine levels, and serum uric ac id) , urine analyses ( glyc osuria, albuminuria) , as well as evidenc e of the heart musc le thic kening seen on elec troc ardiogram ( c ardiac rhythm, signs of myoc ardial isc hemia or myoc ardial infarc tion) and left ventric ular hypertrophy or ec hoc ardiogram. Thorough history, physic al examination and baseline laboratory data should be obtained in the patient whose blood pressure is usually above 1 4 0 /9 0 mm Hg to assess the overall c ardiovasc ular risk and to exc lude identifiable c auses of hypertension.
Risk stratification
In addition to blood pressure, JNC-VI rec ognizes the need to take into c onsideration other c ardiovasc ular risk fac tors, target organ damage and c oexistent c ardiovasc ular disease to determine the overall risk profile of eac h patient and the need for drug therapy. In patients who have a low overall c ardiovasc ular risk, even with a blood pressure as high as 1 6 0 /1 0 0 mm Hg, lifestyle modific ations alone are rec ommended initially. On the other hand, in patients at a high overall risk, suc h as those with diabetes, antihypertensive drug therapy is rec ommended even when the blood pressure is below 1 4 0 /9 0 mm Hg. The treatment goal in these patients is a blood pressure of less than 1 3 0 /8 5 mm Hg. In patients at risk, immediate drug therapy may be nec essary.
H ypertension treatments
Today, there is a general agreement that not only severe but also mild-moderate hypertension should be treated. There is no full c onsensus on when to start antihypertensive treatment, and what is the first line drug treatment. The goal of antihypertensive therapy has to be individual in order to optimize the benefits and minimize the risk for eac h patient.
Antihypertensive drugs should be given initially in a relatively low dosage to avoid blood pressure lowering. The need to "start low and go slow" is even greater in the elderly, whose blood pressure should be reduc ed by gradual titration
The list of the more common approaches:
• • Limit alc ohol intake to no more than 3 0 ml of ethanol ( 7 2 0 ml of beer, 3 0 0 ml of wine, or 6 0 ml of 1 0 0 -proof whiskey) pe r day or 1 5 ml of ethanol pe r day
• Inc rease aerobic physic al ac tivity ( 3 0 -4 5 min most days of the week)
• Reduc e sodium intake to no more than 1 0 0 mmol/d ( 2 .4 g of sodium or 6 g of sodium c hloride)
• Close supervision and spec ialist advic e are needed when there is established and signific ant renal impairment. † Caution with ACE inhibitors and angiotensin II rec eptor antagonists in peripheral vasc ular disease bec ause of assoc iation with renovasc ular disease. ‡ If ACE inhibitor indic ated. § â-bloc kers may worsen heart failure, but in spec ialist hands may be used to treat heart failure.
The c ombinations of different antihypertensive drugs should be added until the goal blood pressure below 1 4 0 / 9 0 mmHg is reac hed, and even lower in those patients with renal insuffic ienc y, diabetes or c ongestive heart failure
Coronary heart disease
Some 7 million Americ ans suffer from c oronary heart disease ( CHD) , the most c ommon form of heart disease. CHD is the number one killer of both men and women in the U.S. Eac h year, more than 5 0 0 ,0 0 0 Americ ans die of heart attac ks c aused by CHD.
Many of these deaths c ould be prevented bec ause CHD is related to c ertain aspec ts of lifestyle. Risk fac tors for CHD inc lude hypertension, high blood c holesterol, smoking, obesity, and physic al inac tivity -all of whic h c an be c ontrolled. Although medic al treatments for heart disease have c ome a long way, the c ontrol of risk fac tors remains the key to preventing illness and death from CHD.
Risk factors that increase the risk of developing coronary heart disease:
Controllable:
• • Gender • Heredity ( family history of CHD)
• Age Approximately 4 to 5 million patients will be evaluated in US emergenc y departments for c hest pain. Of these patients 2 million will be diagnosed as having an ac ute isc hemic syndrome. More than half a million of these patients will be hospitalized with a diagnosis of unstable angina, and 1 .5 million will experienc e an ac ute myoc ardial infarc tion ( AMI) . Of the 1 .5 million AMI patients, approximately half a million will die, and 5 0 % of these deaths will oc c ur within the first hour. Inc luding prehospital mortality, the first prolonged attac k of isc hemic pain has a 3 4 % fatality rate.
Symptoms of coronary heart disease
The term "ac ute c oronary syndrome" has bec ome c ommonly used to refer to patients presenting with isc hemic c hest pain. Chest pain ( angina) or shortness of breath may be the earliest sign of CHD. The other c linic al manifestations of CHD are: heaviness, tightness, pain, burning, pressure, or squeezing, usually behind the breastbone but sometimes also in the arms, nec k, or jaws. Nevertheless, some people have heart attac ks without ever having any of these symptoms.
Nomenc lature of ac ute c oronary syndromes ( ACS) :
• Unstable angina All of the c oronary syndromes are initiated by the same event -rupture of an unstable, lipid-ric h atheromatous plaque in an epic ardial artery. Plaque disruption and fissuring ac tivates platelet adhesion, fibrin c lot formation, and c oronary thrombosis. Without flow restric tion these plaques do not c ause c linic al angina. Suc h plaques, however, have a lipid-ric h c ore that makes them soft and prone to rupture. Inflammatory c ells have been found in areas of plaque rupture. Stable plaques have less lipid and a thic k c ap that makes them more resistant to fissuring and formation of thrombi.
Diagnosis and tests for coronary heart disease
There is no single simple test for the diagnosis of CHD. Various diagnostic proc edures have been used to establish CHD, after taking c areful medic al history and physic al examination to determine its extent and severity, and to rule out other possible c auses of symptoms.
An examination for CH D may include the following tests:
• New blood tests, whic h measure the level of partic ular enzyme markers ( CK isoforms, troponin T and I, myoglobin) that rise with heart tissue damage, also help quic kly diagnose a heart attac k.
• Elec troc ardiogram ( ECG) is a graphic rec ord of the elec tric al ac tivity of the heart. Abnormal heartbeats and some areas of damage, inadequate blood flow, and heart enlargement c an be detec ted on the rec ords.
• Exerc ise stress test ( also c alled a treadmill test or exerc ise ECG) is used to rec ord the heartbeat during exerc ise and blood pressure. In the test, an ECG is done before, during, and after exerc ising on a treadmill. ECG identifies any exerc ise stress-related abnormalities. Breathing rate may be measured as well. Exerc ise tests are useful but are not c ompletely reliable; false positives ( showing a problem where none exists) and false negatives ( showing no problem when something is wrong) are fairly c ommon.
• Nuc lear sc anning is sometimes used to show damaged areas of the heart and expose problems with the heart's pumping ac tion. A small amount of radioac tive material is injec ted into a vein, usually in the arm. A sc anning c amera rec ords the nuc lear material that is taken up by heart musc le ( healthy areas) or not taken up ( damaged areas) .
• Coronary angiography ( or arteriography) is a test used to explore c oronary arteries by a series of x-rays. During an angiogram a fine, long flexible tube ( c atheter) is inserted into the artery of an arm or leg and passed through the tube into the arteries of the heart. The heart and blood vessels are then filmed while the heart pumps. Angiogram shows the flow within the c oronary arteries and identifies any areas of narrowing or bloc kage c aused by atherosc lerosis.
Concepts of treatment and assessment
One of the major insights from the reperfusion era is that signific ant myoc ardial salvage is ac hieved not just from thrombolytic agents. Important benefits in long-term mortality and morbidity emerge from proper and early use of oxygen, ß -bloc kers, nitroglyc erin, aspirin, heparin, and angiotensin-c onverting enzyme ( ACE) inhibitors. From these insights has c ome the c onc ept of three types of therapy:
• Reperfusion therapy -either thrombolytic s or primary PTCA
• Adjunc tive therapy -agents given instead of or in addition to thrombolytic s
• Conjunc tive therapy -agents given to enhanc e the benefits of thrombolytic s
Modifying lifestyles in populations c an have major protec tive effec ts against high blood pressure and various c ardiovasc ular diseases. Lowering high blood pressure dec reases death from stroke, c oronary events and heart failure, slows progression of renal failure, prevents progression to severe c omplic ations of hypertension, and reduc es all-c ause mortality.
The goal of various international ac tions is to reduc e morbidity, disability and premature mortality due to c ardiovasc ular diseases with spec ial attention to the prevention and c ontrol of hypertension by sharing knowledge, experienc e and tec hnology in hypertension prevention among interested parties. Although medic al treatments for heart disease have c ome a long way, the c ontrol of risk fac tors remains the key to preventing illness and death from c oronary heart disease.
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